Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 500 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 500 mg, the generic version of Zytiga® Tablets, 500 mg, of Janssen Biotech Inc.

According to IQVIATM sales data for the 12 month period ending March 2022, the Zytiga® Tablets, 500 mg market achieved annual sales of approximately $260.2 million*.

Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 49 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 392.50 as compared to the previous close of Rs. 406.10. The total number of shares traded during the day was 25251 in over 1183 trades.

The stock hit an intraday high of Rs. 400.95 and intraday low of 390.75. The net turnover during the day was Rs. 9971738.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA FinalApproval AbirateroneAcetateTablets Zytiga